



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/762,210				
Filing Date	January 20, 2004				
First Named Inventor	Ronald J. Berenson				
Art Unit	1645				
Examiner Name					
Attorney Docket No.	980034.417C5				

ENCLOSURES (check all that apply)								
Fee Transmittal Fee Attache Amendment/Re After Final Aftidavits/de Extension of Tir Express Abanda Request Supplemental Ir Disclosure State PTO-1449 Cited Reference Certified Copy of Document(s) Response to Mi under 37 C.F.R. Response to Mi Parts/Incomplet	eclaration(s) me Request conment information ement; Form es of Priority dissing Parts 1.52 or 1.53 dissing		Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund		CD(s), Number of CD(s) After Allowance Communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):			
Remarks				<u> </u>				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Individual Name Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461		Ph.D., Patent Agent	Customer Number 00500					
Signature Chille Va Nath								
Date November 1, 2004								
	//							
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.								
Typed or printed name Lawrence Teague								
Signature Date: November 1, 20					e: November 1, 2004			
This collection of information is	refuired by 87 CFR 1 5	The	information is required to obtain or retain a benefit	by the	public which is to file (and by the USPTO to			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV 0 3 2004

PATENT

The entity that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Vovember 1, 2004

Date

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Ronald J. Berenson et al.

Application No.

: 10/762,210

Filed

January 20, 2004

For

ACTIVATION AND EXPANSION OF CELLS

Art Unit

: 1645

Docket No.

980034.417C5

Date

: November 1, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they

are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 Cited References (10)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\527305

Sheet <u>1</u> of <u>1</u>

FORM PTO-1449)	U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO. APPLICATION NO.						
(REV.7-80) PATENT AND TRADEMARK OFFICE			980034.417C5 10/762,210								
SUPPLEMENTAL				APPLICANTS							
information disclosure statement				Ronald J. Berenson et al.							
(Use we'ven I sheets if necessary)			FILING DATE			UP ART UNIT					
/		<u>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</u>			January 20, 2004		164	15	<u>.</u>		
WOV 0 3 2004 U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL	DOCUMENT NUMBER		DATE		NAME	CLASS		SUBCLASS	FILING DATE IF APPROPRIATE		
	AA	ADEMI									
	AB										
	AC										
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE		COUNTRY				TRANSI	LATION	
		Document Hember	J.1.2						YES	NO	
	AD	WO 01/62895	08/30/01	WIPO		- - ,, ,					
	AE	WO 02/098361	12/12/02	WIPO			٠			,	
	AF	WO 03/024989	03/27/03	WIPO					·		
	AG										
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
	АН	Bonyhadi, M.	et al., "Aut	ologous T	Cell Therapy for B-CL		lood	100(11), A	bstrac	t No.	
		774, November Frohlich, M.V	 _		vation and Expansion of	of T C	ells i	from the Pe	eripher	al	
	AI	Blood of Mul	Multiple Myeloma Patients Using the Xcellerate TM Process," <i>Blood 100</i> (11),								
			Abstract No. 5259, November 16, 2002.								
	AJ		Grosmaire, L. et al., "Ligation of CD2 Amplifies Anti-CD3 X Anti-CD28-Mediated Ex Vivo								
'		1	Activation and Expansion of T Cells," <i>Blood 96</i> (11 part 2): 40b, Abstract No. 3834,								
		November 16							· · · · · · · · · · · · · · · · · · ·		
	AK	· ·	Hou, J.W. et al., "Naïve (CD45RA+) vs Memory (CD45RO+) Status of Human CD4 Cells								
			Greatly Influences Th1/Th2 Polarization Potential," <i>Blood 100</i> (11), Abstract No. 944,								
•			November 16, 2002.								
	AL	ľ	Larsen, A.C. et al., "The ratio of anti-CD3 and anti-CD28 stimulation determines								
			proliferation and IL-2R expression in T cells," Tissue Antigens 55(Suppl. 1): 109, 2000.								
	AM		Long, S.A. et al., "Modulating T Cell Signals Using Xcyte TM Dynabeads® Leads to Selective								
	A.W.	Expansion of	Expansion of Antigen-Specific T Cells," Blood 102(11): 55b, Abstract No. 3922, November								
		16, 2003.									
	AN		_		of conditions for speci		-		dy-coa	ted	
		beads to cells,	" Journal o	of Immunol	ogical Methods 184: 7	1-80, 1	995	•			
EXAMINE	R				DATE CONSIDERED						
* EXAMINI			•		nformance with MPEP 609. Draw		ough c	itation if not in			